Advances and emerging therapies in the treatment of non-alcoholic steatohepatitis

Paul N. Brennan (Lead / Corresponding author), John F. Dillon, Rory McCrimmon

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
38 Downloads (Pure)


Non-alcoholic steatohepatitis (NASH) now represents one of the most prevalent forms of cirrhosis and hepatocellular carcinoma. There have been a number of treatment agents which have undergone assessment in humans, following promising results in animal models. Presently, about 50 therapeutic agents are in various stages of development. Recently, however, there have been a number of exciting positive developments in this landscape, although there are inherent challenges ahead. In this piece, we review the aetiological and pathological basis of NASH progression and putative targets for current therapies. We also discuss some of the likely future directions and difficulties around this complex and growing challenging paradigm.
Original languageEnglish
Pages (from-to)148-155
Number of pages8
JournaltouchREVIEWS in Endocrinology
Issue number2
Early online date22 Nov 2022
Publication statusPublished - 2022


  • Fatty liver disease
  • fibrosis
  • NASH
  • therapeutics


Dive into the research topics of 'Advances and emerging therapies in the treatment of non-alcoholic steatohepatitis'. Together they form a unique fingerprint.

Cite this